What long term benefits does saxagliptin dapagliflozin combination therapy provide?

What improvements in blood sugar control can patients expect over years?

Saxagliptin and dapagliflozin work together through different mechanisms. Saxagliptin keeps incretin hormones active to boost insulin release and reduce glucagon, while dapagliflozin promotes glucose excretion in urine. This dual action lowers HbA1c by 0.5 to 1.0 points more than either drug alone, and those reductions hold up across five-year extensions of clinical trials.

How does this combination affect heart and kidney health in the long run?

The dapagliflozin component drives cardiovascular and renal benefits. Clinical data show it reduces heart failure hospitalizations by 27% and slows progression to end-stage kidney disease. Saxagliptin does not add further cardiovascular harm or benefit, but the pair keeps these SGLT2 effects intact.

What happens to body weight and blood pressure over time?

Dapagliflozin causes consistent weight loss of 2 to 3 kg that stays stable beyond four years. Blood pressure drops 3 to 4 mmHg systolic, similarly保持稳定.

When does patent protection end for this combination?

The fixed-dose tablet containing saxagliptin and dapagliflozin is marketed as Qtern. Qtern's patents expire between 2025 and 2029, depending on regulatory exclusivity extensions. Biosimilar versions could enter after that date.